A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients

June 25, 2018
Principal Investigator: Dean Y Kim, MD
transplant, kidney transplant, transplant institute, kidney, nephrology, cmv
Accepting Participants